Literature DB >> 15044708

Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling.

Federica del Monte1, Djamel Lebeche, J Luis Guerrero, Tsuyoshi Tsuji, Angelia A Doye, Judith K Gwathmey, Roger J Hajjar.   

Abstract

Abnormal intracellular Ca(2+) cycling plays an important role in cardiac dysfunction and ventricular arrhythmias in the setting of heart failure and transient cardiac ischemia followed by reperfusion (I/R). We hypothesized that overexpression of the sarcoplasmic reticulum Ca(2+) ATPase pump (SERCA2a) may improve both contractile dysfunction and ventricular arrhythmias. Continuous ECG recordings were obtained in 46 conscious rats after adenoviral gene transfer of either SERCA2a or the reporter gene beta-galactosidase (beta gal) or parvalbumin (PV), as early as 48 h before and 48 h after 30 min ligation of the left anterior descending artery by using an implantable telemetry system. Sham-operated animals were used for comparison for hemodynamic measurements, whereas within-animal baseline was used for electrocardiographic and echocardiographic parameters. All episodes of nonsustained ventricular tachycardia (VT) and ventricular fibrillation (VF) were counted, and their durations were summed by telemetry. I/R decreased regional cardiac wall thickening as well as the maximal rate of left ventricular pressure rise (+dP/dt) and ventricular pressure fall (-dP/dt). SERCA2a restored regional wall thickening and +dP/dt and -dP/dt to levels seen preoperatively. Regional-wall motion and anterior-wall thickening were improved in the SERCA2a animals, as assessed by echocardiography and piezoelectric crystals. To assess whether these effects are SERCA2a specific, we overexpressed a skeletal-muscle protein, PV, to examine whether Ca(2+) buffering alone can mitigate ventricular arrhythmias. During the first hour after I/R, the rate of nonsustained VT plus VF was 16 +/- 5 episodes per h (n = 6) in the Ad.beta gal group, 22 +/- 6 in the Ad.PV group, and 4 +/- 2(n = 6, P < 0.01) in the Ad.SERCA2a group. The decrease in VT plus VF in the Ad.SERCA2a group was consistent throughout the 48 h of monitoring. These results show that improving intracellular Ca(2+) handling by overexpression of SERCA2a restores contractile function and reduces ventricular arrhythmias during I/R.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044708      PMCID: PMC397450          DOI: 10.1073/pnas.0305778101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Altered cardiac sarcoplasmic reticulum function of intact myocytes of rat ventricle during metabolic inhibition.

Authors:  C L Overend; D A Eisner; S C O'Neill
Journal:  Circ Res       Date:  2001-02-02       Impact factor: 17.367

Review 2.  Calcium fluxes involved in control of cardiac myocyte contraction.

Authors:  D M Bers
Journal:  Circ Res       Date:  2000-08-18       Impact factor: 17.367

3.  Calcium and cardiac rhythms: physiological and pathophysiological.

Authors:  Donald M Bers
Journal:  Circ Res       Date:  2002-01-11       Impact factor: 17.367

Review 4.  Cardiac excitation-contraction coupling.

Authors:  Donald M Bers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

Review 5.  Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization.

Authors:  Lynne Warner Stevenson
Journal:  Circulation       Date:  2003-07-22       Impact factor: 29.690

Review 6.  Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy.

Authors:  Lynne Warner Stevenson
Journal:  Circulation       Date:  2003-07-29       Impact factor: 29.690

7.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a.

Authors:  S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

9.  Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.

Authors:  F del Monte; E Williams; D Lebeche; U Schmidt; A Rosenzweig; J K Gwathmey; E D Lewandowski; R J Hajjar
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

10.  Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats.

Authors:  C F Opitz; G F Mitchell; M A Pfeffer; J M Pfeffer
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

View more
  82 in total

1.  Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a.

Authors:  Ilka Pinz; Rong Tian; Darrell Belke; Eric Swanson; Wolfgang Dillmann; Joanne S Ingwall
Journal:  J Biol Chem       Date:  2011-01-29       Impact factor: 5.157

2.  Return of calcium: manipulating intracellular calcium to prevent cardiac pathologies.

Authors:  Yibin Wang; Joshua I Goldhaber
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 3.  Regenerative therapies in electrophysiology and pacing: introducing the next steps.

Authors:  Gerard J J Boink; Michael R Rosen
Journal:  J Interv Card Electrophysiol       Date:  2010-12-16       Impact factor: 1.900

4.  New experimental evidence for mechanism of arrhythmogenic membrane potential alternans based on balance of electrogenic I(NCX)/I(Ca) currents.

Authors:  Xiaoping Wan; Michael Cutler; Zhen Song; Alain Karma; Toshio Matsuda; Akemichi Baba; David S Rosenbaum
Journal:  Heart Rhythm       Date:  2012-06-19       Impact factor: 6.343

Review 5.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 6.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

7.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

8.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

9.  Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury.

Authors:  Persoulla Nicolaou; Patricia Rodriguez; Xiaoping Ren; Xiaoyang Zhou; Jiang Qian; Sakthivel Sadayappan; Bryan Mitton; Anand Pathak; Jeffrey Robbins; Roger J Hajjar; Keith Jones; Evangelia G Kranias
Journal:  Circ Res       Date:  2009-03-19       Impact factor: 17.367

10.  Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo.

Authors:  Nathan J Palpant; Louis G D'Alecy; Joseph M Metzger
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.